Phase II Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage of Small Cell Lung Cancer
Two 21-day cycles of pemetrexed (500 milligrams per square meter [mg/m2] intravenous [IV]
infusion) and carboplatin (target area under the curve [AUC] 5 IV infusion) followed by two
21-day cycles of pemetrexed (500 mg/m2 IV infusion) and carboplatin (target AUC 5 IV
infusion) with concurrent radiotherapy (2 Gray [Gy] per fraction, 5 fractions per week, up
to a dose of 50 Gy is administered).
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Proportion of Patients With a Complete or Partial Response (Overall Response Rate [ORR])
baseline to measured response after chemotherapy and radiation
No
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Italy: Ministry of Health
10015
NCT00494026
September 2007
October 2008
Name | Location |
---|